Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Empowered Funds LLC

Empowered Funds LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 681.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 62,052 shares of the company's stock after purchasing an additional 54,114 shares during the quarter. Empowered Funds LLC owned about 0.06% of Neurocrine Biosciences worth $7,150,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Plato Investment Management Ltd boosted its holdings in Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company's stock valued at $1,263,000 after purchasing an additional 10,548 shares during the last quarter. Redwood Investment Management LLC acquired a new position in Neurocrine Biosciences in the 1st quarter valued at about $642,000. Shell Asset Management Co. lifted its holdings in shares of Neurocrine Biosciences by 132.8% in the 1st quarter. Shell Asset Management Co. now owns 6,828 shares of the company's stock worth $942,000 after acquiring an additional 3,895 shares during the last quarter. Tidal Investments LLC lifted its holdings in shares of Neurocrine Biosciences by 57.8% in the 1st quarter. Tidal Investments LLC now owns 9,542 shares of the company's stock worth $1,316,000 after acquiring an additional 3,497 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter worth approximately $5,848,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 4.4 %

NASDAQ:NBIX traded down $5.44 during midday trading on Friday, hitting $117.44. 1,255,345 shares of the company were exchanged, compared to its average volume of 997,520. The company has a fifty day simple moving average of $118.50 and a 200 day simple moving average of $132.63. Neurocrine Biosciences, Inc. has a fifty-two week low of $107.84 and a fifty-two week high of $157.98. The company has a market capitalization of $11.89 billion, a PE ratio of 31.49 and a beta of 0.35.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on NBIX. BMO Capital Markets decreased their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a report on Thursday, October 17th. Barclays decreased their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating on the stock in a report on Monday, September 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. Raymond James restated an "outperform" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.